Education
About Us
Working with TipRanks
Follow Us
2cureX AB (DE:2QE)
FRANKFURT:2QE
2QE Stock Chart & Stats
€0.13
<€0.01(3.70%)
At close: 4:00 PM EST
€0.13
<€0.01(3.70%)
Day’s Range― - ―
52-Week Range€0.02 - €0.49
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€3.34M
Enterprise Value€31.26M
Total Cash (Recent Filing)€3.13M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Feb 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding25,102,917
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.75
Price to Sales (P/S)0.00
P/FCF Ratio-1.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetHaving no debt materially reduces fixed obligations and financial distress risk, giving management flexibility to fund operations via equity, partnerships, or grant funding. This durable balance-sheet strength supports continued R&D and commercialization efforts over the next several months.
Platform-focused Business ModelA clear platform offering—functional drug response testing for precision oncology—creates multiple durable revenue vectors: per-test clinical fees, pharma collaborations, and licensing. Structural demand for personalized oncology diagnostics supports recurring, contractable revenue potential over time.
Improving Cash Burn TrendMaterial narrowing of losses and reduced cash burn in 2024 indicates improving operating discipline or commercialization traction. A sustained improvement trend lowers near-term refinancing pressure and increases the chance of reaching breakeven within a multi-quarter horizon if continued.
Bears Say
Near-zero RevenueVolatile and effectively negligible revenue (declines to near-zero) signals weak commercial traction and makes scaling the test platform uncertain. Without sustainable test volumes or contracted revenue, the business struggles to convert R&D into durable, predictable income.
Negative Cash GenerationPersistent negative operating and free cash flow necessitate external funding to sustain R&D and commercialization. Over the medium term this creates dilution or financing risk, constrains reinvestment in sales/clinical adoption, and limits strategic flexibility if markets tighten.
Shrinking Equity And AssetsErosion of the capital base reduces the company’s financial cushion and ability to absorb setbacks. Even with no debt, a shrinking equity/asset base heightens solvency risk and increases the likelihood of needing dilutive funding or strategic partnerships to preserve operations.
2QE FAQ
What was 2cureX AB’s price range in the past 12 months?
2cureX AB lowest stock price was €0.02 and its highest was €0.49 in the past 12 months.
What is 2cureX AB’s market cap?
2cureX AB’s market cap is €3.34M.
When is 2cureX AB’s upcoming earnings report date?
2cureX AB’s upcoming earnings report date is Feb 26, 2026 which is in 5 days.
How were 2cureX AB’s earnings last quarter?
Currently, no data Available
Is 2cureX AB overvalued?
According to Wall Street analysts 2cureX AB’s price is currently Overvalued.
Does 2cureX AB pay dividends?
2cureX AB does not currently pay dividends.
What is 2cureX AB’s EPS estimate?
2cureX AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 2cureX AB have?
2cureX AB has 25,102,917 shares outstanding.
What happened to 2cureX AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of 2cureX AB?
Currently, no hedge funds are holding shares in DE:2QE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
2cureX AB
2cureX AB (publ) operates as a medtech company in Europe. Its principal product is IndiTreat, an IVD test, which helps to predict cancer patient's response and resistance to different drugs and select the appropriate treatment. The company is also conducting various clinical programs for IndiTreat for breast colorectal, ovarian, and pancreatic cancers. 2cureX AB (publ) was incorporated in 2006 and is based in Copenhagen, Denmark.
Technical Analysis
OncoZenge AB
―
LIDDS AB
―
ExpreS2ion Biotech Holding AB
―
CombiGene AB
―
Sprint Bioscience AB
―